About

About Allsino Pharmaceutical Co., Ltd. Allsino pharmaceutical Co., Ltd. Your Premier Partner in Small Molecule & Peptide CDMO Services Company Overview Founded in May 2004, Allsino Biopharmaceutical Co., Ltd.is a wholly-owned subsidiary of Sinopep-Allsino Biopharmaceutical Co., Ltd. (Stock Code: 688076), a publicly traded company on the Shanghai Stock Exchange's STAR Market . Headquartered in Hangzhou, China, Allsino is a globally recognized Contract Development and Manufacturing Organization (CDMO), specializing in the research, development, and production of innovative small molecule drugs, advanced pharmaceutical intermediates, and peptide fragments. With a steadfast commitment to quality and innovation, Allsino serves as a critical bridge between early-stage drug discovery and commercial manufacturing, helping partners accelerate timelines and reduce risks. Strategic Locations: R&D and GMP Manufacturing Allsino operates an integrated Hangzhou R&D + Jiande Manufacturing" dual-site model to ensure seamless technology transfer and scalable production. R&D Center (Hangzhou, Zhejiang): Location: Yuhang District, Hangzhou. Status: Recognized as a Provincial Enterprise Research Institute by the Zhejiang Provincial Government . Capabilities: Houses over 100 scientists, including Ph.D. and Master's level chemists. The center focuses on core technologies such as small molecule catalysis, continuous flow chemistry, and solid-phase peptide synthesis. - GMP Commercial Production Base (Jiande, Zhejiang): - Location:Jiande City, Hangzhou. - Scale: Spanning 60,000+ square meters(approx. 146 Mu) . - Certification: Operates under strict cGMP standards, compliant with US FDA, EDQM, and NMPA regulations . In 2023, the facility successfully passed the NMPA GMP evaluation for APIs . Core Business & Technical Expertise Allsino is an innovation-driven entity that has successfully initiated and developed over 300 projects across various therapeutic areas, including oncology, central nervous system (CNS) disorders, and metabolic diseases (including GLP-1 analogs for diabetes and obesity) . Key Services: Process Development & Scale-up: From laboratory synthesis to multi-ton commercial production. - Custom Synthesis: Advanced intermediates, Registered Starting Materials (RSMs), and GMP-grade Active Pharmaceutical Ingredients (APIs) . Peptide CDMO Services:Specializing in peptide fragments and oligonucleotides. Commercial Manufacturing: Supporting NDA filings and commercial launch. Quality & Global Recognition Allsino’s commitment to pharmaceutical excellence is validated by its long-standing partnerships with top-tier global pharmaceutical companies. Global Partnerships:The company has established long-term technical collaborations with Fortune 500 pharmaceutical companies such as ****** . Industry Award: In 2022, Allsino was honored with the "SK Pharmteco Preferred Partner Award" at CPhI Frankfurt. Notably, Allsino was the only Chinese company selected among nearly 100 global suppliers to receive this distinction . Intellectual Property: Holds over 20 patents (including inventions and utility models) . Certifications - US FDA (cGMP) - NMPA (China GMP) - ISO 9001, ISO 14001, ISO 45001 Workforce & Assets Employees:500+ , including a highly educated technical team of 240+ professionals (6 Ph.D.s, 16 Master's degrees) . Annual R&D Investment: Consistently exceeds 10% of revenue, ensuring continuous technological innovation . Contact Information Website:[www.allsino.com](http://www.allsino.com) R&D Center Address: 4F, Building 1, No. 39 Keji Avenue, Yuhang District, Hangzhou, Zhejiang, China (Postal Code: 311121) Manufacturing Base Address:No. 18 Fenghe Road, Xiaya Town, Jiande City, Hangzhou, Zhejiang, China (Postal Code: 311606) Phone: +86-571-89961929 / +86-571-88180350 Email (Sales): sales@allsino.com Allsino pharmaceutical Co., Ltd.—Bridging Innovation from Lab to Market.